CTNM vs. SKYE

Last updated Jun 5, 2026

CTNM (Contineum Therapeutics, Inc) and SKYE (Skye Bioscience, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, CTNM returned 179.82% vs -65.41% for SKYE. At a 0.21 correlation, their price movements are largely independent.

Performance

CTNM vs. SKYE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Contineum Therapeutics, Inc (CTNM) and Skye Bioscience, Inc (SKYE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CTNM achieves a 7.96% return, which is significantly higher than SKYE's 3.35% return.

CTNM

• 1D: -1.12%
• 1M: -14.25%
• YTD: 7.96%
• 6M: 12.39%
• 1Y: 179.82%
• 3Y*: —
• 5Y*: —
• 10Y*: —

SKYE

• 1D: 0.61%
• 1M: -11.67%
• YTD: 3.35%
• 6M: -35.97%
• 1Y: -65.41%
• 3Y*: -42.50%
• 5Y*: -55.62%
• 10Y*: -39.35%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CTNM vs. SKYE - Yearly Performance Comparison

	2026 (YTD)	2025	2024
CTNM Contineum Therapeutics, Inc	7.96%	-21.98%	-4.87%
SKYE Skye Bioscience, Inc	3.35%	-73.51%	-74.46%

Correlation

The correlation between CTNM and SKYE is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.19
Correlation (All Time) Calculated using the full available price history since Apr 8, 2024	0.21

Fundamentals

Market Cap CTNM : $460.76M SKYE : $30.75M
EPS CTNM : -$1.91 SKYE : -$1.45
PB Ratio CTNM : 1.84 SKYE : 3.41
Total Revenue (TTM) CTNM : $0.00 SKYE : $0.00
Gross Profit (TTM) CTNM : -$245.00K SKYE : -$180.01K
EBITDA (TTM) CTNM : -$62.61M SKYE : $10.92M

Return for Risk

CTNM vs. SKYE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CTNM

CTNM Risk / Return Rank: 89
CTNM Sharpe Ratio Rank: 89
CTNM Sortino Ratio Rank: 87
CTNM Omega Ratio Rank: 83
CTNM Calmar Ratio Rank: 94
CTNM Martin Ratio Rank: 92

SKYE

SKYE Risk / Return Rank: 20
SKYE Sharpe Ratio Rank: 17
SKYE Sortino Ratio Rank: 23
SKYE Omega Ratio Rank: 23
SKYE Calmar Ratio Rank: 14
SKYE Martin Ratio Rank: 21

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CTNM vs. SKYE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Contineum Therapeutics, Inc (CTNM) and Skye Bioscience, Inc (SKYE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CTNM	SKYE	Difference
Sharpe ratio: Return per unit of total volatility	2.06	-0.57	+2.63
Sortino ratio: Return per unit of downside risk	2.86	-0.33	+3.19
Omega ratio: Gain probability vs. loss probability	1.34	0.96	+0.39
Calmar ratio: Return relative to maximum drawdown	6.06	-0.75	+6.81
Martin ratio: Return relative to average drawdown	13.94	-1.00	+14.94
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CTNM vs. SKYE - Sharpe Ratio Comparison

The current CTNM Sharpe Ratio is 2.06, which is higher than the SKYE Sharpe Ratio of -0.57. The chart below compares the historical Sharpe Ratios of CTNM and SKYE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CTNM	SKYE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.06	-0.57	+2.63
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.43	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	-0.29	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.12	-0.36	+0.24

Drawdowns

CTNM vs. SKYE - Drawdown Comparison

The maximum CTNM drawdown since its inception was -84.37%, smaller than the maximum SKYE drawdown of -99.96%. Use the drawdown chart below to compare losses from any high point for CTNM and SKYE.

Drawdown Indicators

	CTNM	SKYE	Difference
Max Drawdown Largest peak-to-trough decline	-84.37%	-99.96%	+15.59%
Max Drawdown (1Y) Largest decline over 1 year	-29.84%	-87.85%	+58.01%
Max Drawdown (3Y) Largest decline over 3 years	—	-96.79%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-98.79%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-99.83%	—
Current Drawdown Current decline from peak	-43.26%	-99.94%	+56.68%
Average Drawdown Average peak-to-trough decline	-41.12%	-94.95%	+53.83%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.96%	65.33%	-52.37%

Volatility

CTNM vs. SKYE - Volatility Comparison

The current volatility for Contineum Therapeutics, Inc (CTNM) is 16.21%, while Skye Bioscience, Inc (SKYE) has a volatility of 28.43%. This indicates that CTNM experiences smaller price fluctuations and is considered to be less risky than SKYE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CTNM	SKYE	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.21%	28.43%	-12.22%
Volatility (6M) Calculated over the trailing 6-month period	48.25%	63.71%	-15.46%
Volatility (1Y) Calculated over the trailing 1-year period	88.08%	115.70%	-27.62%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	83.28%	130.81%	-47.53%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.28%	137.36%	-54.08%

Dividends

CTNM vs. SKYE - Dividend Comparison

Neither CTNM nor SKYE has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both CTNM and SKYE in my portfolio?

CTNM and SKYE have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CTNM or SKYE?

SKYE has higher volatility (28.43%) compared to CTNM (16.21%). In terms of maximum drawdown, CTNM dropped -84.37% vs SKYE's -99.96%.

Which has better risk-adjusted returns?

CTNM currently has the higher Sharpe Ratio (2.06 vs -0.57), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.